Cargando…

Chimeric antigen receptor T cells for gamma–delta T cell malignancies

Detalles Bibliográficos
Autores principales:	Wawrzyniecka, P. A., Ibrahim, L., Gritti, G., Pule, M. A., Maciocia, P. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807386/ https://www.ncbi.nlm.nih.gov/pubmed/34389804 http://dx.doi.org/10.1038/s41375-021-01385-0

Ejemplares similares

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation
por: Capsomidis, Anna, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies
por: Lopez, Ernesto, et al.
Publicado: (2023)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)

Large-scale manufacturing of base-edited chimeric antigen receptor T cells
por: Woodruff, Rosie, et al.
Publicado: (2023)

Preferential usage of the Fc receptor gamma chain in the T cell antigen receptor complex by gamma/delta T cells localized in epithelia
Publicado: (1994)

Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells
por: Maher, John
Publicado: (2012)

Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
por: Shen, Chunyi, et al.
Publicado: (2020)

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
por: Totzeck, Matthias, et al.
Publicado: (2022)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
por: Polgárová, Kamila, et al.
Publicado: (2022)

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
por: Yang, Zhihuan, et al.
Publicado: (2023)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
por: Li, Fanlin, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
por: Klampatsa, Astero, et al.
Publicado: (2017)

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
por: Chen, K H, et al.
Publicado: (2017)

Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival
por: Winkelmann, Michael, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
por: Reinhardt, Bryanna, et al.
Publicado: (2023)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis
por: Hunter, Bradley D., et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma
por: Tang, Xin, et al.
Publicado: (2021)

Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data
por: Lambert, Jérôme, et al.
Publicado: (2023)

Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
por: Lin, Richard J., et al.
Publicado: (2020)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

T cell receptor gamma/delta chain diversity
Publicado: (1988)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021)

The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies
por: Zheng, Diwei, et al.
Publicado: (2022)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
por: Zhang, Hao, et al.
Publicado: (2021)

P1466: CD7 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR ADULT PATIENTS WITH REFRACTORY AND RELAPSED T CELL MALIGNANCIES
por: Zhang, Y., et al.
Publicado: (2022)

Tolerance of T cell receptor gamma/delta cells in the intestine
Publicado: (1993)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
por: Sun, Wei, et al.
Publicado: (2023)

Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies
por: Garcia-Prieto, Carlos A, et al.
Publicado: (2021)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Apoptosis Induced via Gamma Delta T Cell Antigen Receptor “Blocking” Antibodies: A Cautionary Tale
por: Dutta, Indrani, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u0kaf248950in64g8j10cbn12o